In children with bilateral Wilms' tumor, the therapy should aim at maximal preservation of renal parenchyma and function. Local radiotherapy may give rise to second malignant neoplasms and may impair renal function. We present a therapeutic strategy without any irradiation. Three children were diagnosed with bilateral Wilms' tumor at ages from 6 months to 5 years. Each patient had a massive tumor with local stage III on one side; one had pulmonary metastases. The therapeutic strategy was first to obtain tissue for histology by percutaneous needle biopsy, to administer pre-operative chemotherapy until desired tumor shrinkage, and then to perform kidney-sparing resective surgery. After a period of conventional chemotherapy, the patients were consolidated with high-dose (HD) melphalan and ABMT. Renal parenchyma spared post-surgery (right/left) was 0%/70%, 60%/40% and 40%/60% of the original kidney volumes. The toxicity of the ABMT procedure was mild, the patients engrafted promptly, and were discharged on days +14 to +27. All patients survive disease-free, 3 years 4 months to 4 years 5 months post-transplant. Our program resulted in good preservation of renal parenchyma and normal function, and we consider the risk of this ABMT program smaller than the late consequences of local radiotherapy for children with bilateral Wilms' tumor. The therapeutic strategy described merits further evaluation. Keywords: autologous bone marrow transplantation; melphalan, high-dose; pre-operative chemotherapy; renal function; renal growth; Wilms' tumor, bilateral Wilms' tumor is one of the pediatric malignancies with the best success of cure today.
NWTS-3 was only 17%. 1 Even after relapse, a prolonged disease-free survival of 38% has been described in NWTS-2 and NWTS-3. 3 The success in curing this disease is due to the combined modality therapy with surgery, radiotherapy and chemotherapy.
Bilateral Wilms' tumor, ie stage V, is a special circumstance. Synchronous bilateral Wilms' tumor accounts for 5-10% of all patients. 4 In contrast to unilateral Wilms' tumor, there has not been uniform agreement about the therapeutic strategy in the management of bilateral Wilms' tumor. The surgical management has evolved from primary surgical extirpation to preservative, resective measures after pre-operative chemotherapy. [4] [5] [6] A common recommendation has previously been to perform initial nephrectomy on the more affected side, to proceed with chemotherapy aiming at a possible later resection on the remaining kidney. Initial biopsy only, followed by pre-operative chemotherapy, reduces the tumor burden and has been more recently recommended to facilitate parenchymal-sparing surgery, instead of primary nephrectomy. [6] [7] [8] The decision about tumor site or abdominal irradiation should be based on the local tumor stage. Accordingly, advanced stage (III) tumors or cases with residual tumor post-surgery would require local irradiation, in the worst cases to both tumor sites or whole abdomen. Post-nephrectomy radiotherapy on the tumor bed is a totally different issue as opposed to the case in which a partially resected kidney is left behind. Irradiation may, in a dose-dependent fashion, cause radiation nephritis and/or impairment of renal function. 9 Furthermore, stage V Wilms' tumor is probably an indicator of underlying genetic predisposition with an increased risk of a second Wilms' tumor (metachronous bilateral Wilms), as well as risk of other second malignant neoplasms (SMN). The observed increased risk of SMNs in bilateral Wilms' tumor patients 10, 11 has, however, not been confirmed by NWTS. 12 That tumor formation depends on two rate-limiting genetic events has been proposed in Knudson and Strong's model for Wilms' tumor. 13 Radiotherapy offers the second genetic event required for tumorigenesis in these patients, analogously to patients with retinoblastoma, 14 and should therefore preferably be avoided.
The duration and intensity of chemotherapy depends very much on the other therapeutic modalities used. Threedrug conventional chemotherapy regimens are today commonly used in patients with bilateral Wilms' tumor. High-dose chemotherapy with bone marrow rescue has a developing role primarily in recurrent high-risk or refractory Wilms' tumor. So far, data are limited and follow-up times have been relatively short. The European Blood and Marrow Transplantation (EBMT) Group reported on 25 children who received high-dose chemotherapy plus ABMT as part of their salvage therapy. 15 Nine of the 25 survived. Although seven different high-dose regimens were used, melphalan was given to 20, associated with vincristine or etoposide. 15 Our own experience has been encouraging with high-dose melphalan of 210 mg/m 2 alone, when used in children with very poor risk Wilms' tumor (unpublished data).
In the present study we describe three patients with bilateral Wilms' tumor for whom we have successfully used late kidney-sparing surgery after pre-operative chemotherapy, and consolidation with high-dose melphalan and bone marrow rescue. Radiotherapy was totally omitted.
Patients and methods
Three patients with bilateral Wilms' tumor participated in this pilot study. There were two males and one female, aged 6 months, 3 years 10 months, and 5 years at diagnosis. None of the children had associated anomalies. Oral witnessed informed consent (as is customary in Finland) was obtained from the parents. The study has been approved by the Institutional Review Board.
The therapeutic strategy was as follows. After initial imaging studies with ultrasound and CT scan, percutaneous posterior needle biopsy was performed on the side of the larger tumor mass, to obtain tissue cores for histology. 16 Pre-operative chemotherapy usually with up to three drugs (vincristine, actinomycin D, cyclophosphamide) was administered until desired tumor shrinkage was obtained. After bilateral renal resections for gross surgical extirpation of the tumors, chemotherapy was continued with three drugs according to the NWTS-3 protocols. 1 No radiotherapy was administered. Finally, consolidation therapy with high-dose melphalan and bone marrow rescue was given ( Table 1 ). The duration of therapy ranged in total 13-16 months, and from the last resective surgery to ABMT, 5-12 months.
Autologous bone marrow was harvested on an appropriate occasion during the chemotherapy period by using a standard procedure. The marrow was red cell-depleted 17 and cryopreserved in liquid nitrogen until used. High-dose chemotherapy consolidation was given, in first remission, with melphalan of 140 mg/m 2 on day Ϫ2 and 70 mg/m 2 on day Ϫ1, followed by autologous bone marrow rescue on day 0. Granulocyte colony-stimulating factor (G-CSF) was administered at 5 g/kg s.c. daily starting on day +1, and continued until the absolute neutrophil count (ANC) exceeded 1000 × 10 6 /l.
Case 1
This boy was 6 months old at diagnosis of bilateral renal tumors ( Figure 1a 2 on days 1 and 4) plus cyclophosphamide (10 mg/kg/day × 3 days); actinomycin D was abandoned due to severe thrombocytopenia. At 11.5 months from the initial diagnosis a third operation was undertaken because three nodules were detected on CT scan. All three nodules were excised with healthy-looking margins from lower pole of the left kidney. Histology revealed only scar tissue. About 70% of renal parenchyma was saved in the left kidney after all these resective measures. No radiotherapy was administered. The patient underwent consolidation with HD-melphalan and bone marrow rescue 16 months from initial diagnosis and 5 months from last surgery. He remains in 1CR, well and disease-free, 4 years 5 months post-transplant and off therapy.
Case 2
This boy was diagnosed at 5 years of age with bilateral Wilms' tumor. The left-sided tumor was massive, originating in the upper pole of the kidney and extending up to the diaphragm. The tumor in the lower pole of the right kidney was smaller (Figure 1b ). There were, in addition, several pulmonary metastases of less than 1 cm in size in the right lung, visible both on CT scan and chest X-ray. Percutaneous posterior needle biopsy of the left-sided tumor revealed Wilms' tumor with favorable histology (FH). Preoperative chemotherapy consisted of three courses of actinomycin D 0.015 mg/kg/day days 1-5 plus vincristine 1.5 mg/m 2 on days 1 and 5, and two courses of vincristine plus cyclophosphamide of 1000 mg/m 2 . Surgical resection was performed 14 weeks from the initial diagnosis after substantial shrinkage of the tumors (Figure 2b) . The left-sided 55 Table 1 Three patients with bilateral Wilms' tumor treated with neoadjuvant chemotherapy, delayed surgery, and consolidation with high-dose melphalan and ABMT 
a After sharp renal resections not considered stage I. Drug doses and schedules given in the case reports. FH = favorable histology; VCR + Dact = vincristine + actinomycin D; VCR + Cy = vincristine + cyclophosphamide; VAC = vincristine + actinomycin D + cyclophosphamide; VAdrC = vincristine + doxorubicin + cyclophosphamide; Adr = doxorubicin; CFU-GM = colony-forming unit, granulocytemacrophage; ANC = absolute neutrophil count; FUO = fever of undetermined origin; D/C = discharged.
tumor had infiltrative growth into the splenic hilum, the diaphragm, and also into the back muscles (local stage III). All macroscopic tumor was removed on both sides along sharp resection lines. All tumor was totally necrotic. About 60% of the right and 40% of the left kidney parenchyma was spared. The pulmonary metastases had disappeared after three courses of initial chemotherapy and surgery was not given. Adjuvant chemotherapy consisted of vincristine, actinomycin D and doxorubicin according to the NWTS-3 protocol. 1 Conventional therapy guidelines would have necessitated irradiation of the left tumor bed, ie most of the abdomen, and the lungs. Instead, high-dose melphalan and autologous bone marrow rescue were given 15 months from the initial diagnosis, 12 months post-surgery. The boy is currently well and in 1 CR, 4 years 3 months post-transplant.
Case 3
This girl was 3 years 10 months old when diagnosed with bilateral Wilms' tumor. The tumor in the upper pole of the right kidney was massive, 16 × 11 × 7 cm in size, dislocating the right lobe of the liver, and verified later at surgery as a sizeable tumor rupture (local stage III). The left kidney contained a 5 cm tumor in the upper pole, plus two smaller nodules at the hilum level and in the lower pole ( Figure  1c) . Percutaneous posterior needle biopsy on the right side confirmed Wilms' tumor with FH. Pre-operative chemotherapy consisted of three courses of vincristine plus actinomycin D, and two courses of vincristine plus cyclophosphamide, as in case 2. Surgical resection was performed after a good response, 10 weeks from the initial diagnosis (Figure 2c) . The left upper pole with the 5 cm tumor was found. Postoperative chemotherapy consisted of vincristine, actinomycin D and doxorubicin according to the NWTS-3 protocol. 1 Two months after surgery, explorative laparotomy was undertaken because tumor recurrence was suspected on CT scan. No tumor was found, and all biopsies taken during the operation were negative. Conventionally this patient would have needed irradiation at least to the right tumor bed which was very large (initially 16 cm in diameter). Instead, the patient underwent high-dose chemotherapy with melphalan and autologous bone marrow rescue while in 1CR, 13 months from the diagnosis and 11 months after resective surgery. She is currently well and disease-free, 3 years 4 months post-transplant.
Results

Toxicity of ABMT
The ABMT procedure described, with the preparative regimen used and with the post-transplant growth factor administration included, was very well tolerated. Toxicity was primarily hematologic, and very mild as compared with many other bone marrow transplant regimens employed in children. During the post-transplant neutropenia, one patient (case 1) had septicemia caused by Streptococcus viridans but the clinical course of the illness was mild, with only 4 days of fever and only 2 days of an ANC Ͻ200 × 10 6 /l. The other two patients had fever of undetermined origin. All received intravenous antibiotics. However, the neutropenias were short-lived and engraftment occurred promptly. An ANC of 500 × 10 6 /l was reached on days +12, +12 and +11 post-transplant, and the platelets were self-sustained over 30 × 10 9 /l at 2.5, 5 and 3.5 weeks, respectively. The total duration of profound neutropenia, with ANC below 200 × 10 6 /l, was only 2, 5 and 4 days, respectively. Mucositis was not seen. The patients were discharged home in good condition on days +25, +27 and +14 (Table 1) .
Outcome of the patients
All three patients survive disease-free at 5 years 9 months, 5 years 6 months, and 4 years 5 months after the initial diagnosis, and 4 years 5 months, 4 years 3 months, and 3 years 4 months post-transplant. All three are doing well, with a good quality of life, normal activity, and no medication.
Outcome of renal status
All the resected kidneys are growing in size, as indicated by the kidney surface area measurements on DMSA renography 18 ( Figure 3 ). Renal parenchyma spared (right/left) post-surgery accounted for 0%/70%, 60%/40% and 40%/60% of the original kidney volumes estimated. As evaluated from the bilateral isotope accumulation on DMSA renography 3-4 years later, proportional renal functions (right/left) were 0%/100%, 64%/36% and 27%/73%, respectively. The glomerular filtration rate, measured by chromium EDTA clearance, 19 has remained within the nor- Renal surface area (cm2)
Years from operation mal range although there has been a trend to slow decrease in relation to body surface area during the follow-up of 3-4 years ( Figure 4) . Levels of serum creatinine and blood urea nitrogen are normal; acid-base balance and serum calcium and phosphate levels are also normal. Growth in height in all three children is developing normally without any loss in individual standard deviation scores, also indicating good health and normal renal function.
Discussion
Our three cases with bilateral Wilms' tumor indicate that it is possible to preserve relatively large amounts of renal parenchyma and good renal function by postponing surgery after a period of neoadjuvant chemotherapy. The amount of renal parenchyma spared was up to 40% in kidneys car- 19 rying massive tumors, and 60-70% on the less affected sides (Figure 2) . The resulting renal function was normal in terms of glomerular filtration rate and the levels of serum creatinine and BUN.
Preservation of maximum amounts of renal parenchyma is important, because patients with bilateral Wilms' tumor run a risk higher than those with unilateral disease of developing second/third Wilms' tumors later. These patients commonly harbor nephrogenic nests in their renal parenchyma and are prone to multifocal disease. In other words, further renal resections may become necessary later. Subsequent renal failure is indeed one of the most serious complications in patients with bilateral Wilms' tumor, [20] [21] [22] with incidences of 16%, 10% and 4% reported from the NWTS 1&2, 3 and 4, respectively. 22 Our patients are still young, 6-10 years of age, and the follow-up is not very long. It remains to be seen how renal size and function will ultimately adapt to growth and development.
When initial nephrectomy is not attempted, a percutaneous posterior needle biopsy for obtaining specimens for histology is much less invasive and more sparing for the patient than biopsies taken at laparotomy 16 although local staging by CT scan only may not be as accurate as through direct inspection.
Pre-operative chemotherapy, with drugs conventionally used in Wilms' tumor, was efficaceous in the present study, as also shown in earlier reports. 2, 16 It is accordingly clear that more renal parenchyma can be spared by surgery postponed until after pre-operative chemotherapy, as compared to up-front resective measures. 6, 7 The kidney-sparing therapeutic strategy, as described above, did not jeopardize survival or outcome.
Radiotherapy has traditionally been one of the treatment modalities in Wilms' tumor. Local irradiation has been omitted, however, in low-stage (I-II) tumors. 1 In bilateral Wilms' tumor, radiotherapy should be administered according to local stage, although definite indications are somewhat less clear regarding bilateral tumors. In the NWTS protocols this has meant staging evaluated at initial surgery. It is harder to apply staging rules after a period of preoperative chemotherapy, particularly after partial kidney resections along sharp resection lines where microscopic or even macroscopic residual tumour may or may not be left behind. This creates difficulty in assessing the true need for local irradiation. More importantly, irradiation is harmful for renal tissue, both in potentially impairing renal function, and, particularly in patients with bilateral Wilms' tumor, in possibly increasing the risk of second malignancies. Total avoidance of radiotherapy would therefore be desirable, not only in low local stages and small tumors, but also in higher local stages and/or massive tumors.
In the present study, radiotherapy was replaced by consolidation with high-dose melphalan and autologous bone marrow rescue. High-dose melphalan is suitable for ABMT programs for patients with Wilms' tumor as an efficacious and non-nephrotoxic agent. This type of ABMT program has very low toxicity today. The duration of neutropenia is substantially shorter when colony-stimulating factors are used, 23 and also the associated mucositis is milder and short-lived or may not be seen at all. A very short preparative regimen, such as 2 days of melphalan, also results in a shorter period of profound neutropenia. The total days with an ANC of Ͻ200 × 10 6 /l were only 2 to 5 days in our three patients. The duration of post-transplant hospital stay was also short (Table 1) . Melphalan could also be administered as a single intravenous dose which would not even necessitate freezing of the autologous marrow. We feel, however, that marrow harvested earlier in the course of the disease, with less cumulative chemotherapy is probably of better quality for prompt engraftment.
The toxicity of our ABMT program was so low that front-line therapy with high-dose melphalan in 1CR patients with bilateral Wilms' tumor as consolidation seems justified, and preferable as compared to its use as salvage therapy after relapse. Before any relapse, there is less cumulative toxicity from previous therapy, probably more renal parenchyma is left, and no radiotherapy has been given; accordingly the patient should tolerate an up-front ABMT program much better. We feel strongly that the risks involved in local radiotherapy for bilateral Wilms' tumor clearly outweigh those associated with high-dose melphalan plus ABMT with colony-stimulating factors for patients in first remission. In the comparison of strategies with radiotherapy vs high-dose melphalan plus ABMT, a larger number of patients is required. The end point should be ultimate renal function, since major differences in survival would not be expected.
As far as the long-term toxicity of high-dose melphalan goes, chemotherapy in general may increase the risk of second cancers. Following chemotherapy for ovarian cancer, some increased risk of leukemia has been observed, although more so with increasing age. 24 With melphalan this risk was dose-dependent. 24 We have not observed any second malignancies after high-dose melphalan in our neuroblastoma patients to date (unpublished data). The cohorts are 11 survivors after single-dose melphalan of 140 mg/m 2 , 25 followed-up for 11-15 years, and 10 survivors after a preparative regimen of cisplatin, etoposide, melphalan of 210 mg/m 2 and total body irradiation, 26 followedup for 3-9 years. In Wilms' tumor patients in general, a cumulative risk of a SMN was 1.6% at 15 years after diagnosis in the NWTS series. 12 Abdominal irradiation increased the risk of SMNs in a dose-dependent manner. 12 In a recent report from SIOP, the cumulative incidence of second cancers was 0.65% at 15 years, the risk being fivefold compared to the general population. 27 In the SIOP studies it seems that the incidence of second malignancies has decreased along with reduction of radiotherapy. 27 We do not advocate ABMT programs for patients with small tumors and low local stages, however. The risk of overtreating is obvious and should be avoided. In addition, when high-dose melphalan and ABMT are included in the treatment program, it is uncertain to date how much conventional chemotherapy should precede consolidation which works best when administered with minimal residual disease.
In conclusion, our pilot study on patients with bilateral Wilms' tumors with pre-operative chemotherapy, late kidney-sparing surgery, and consolidation with high-dose melphalan plus ABMT resulted in good preservation of kidney parenchyma and renal function. Radiotherapy was totally
